Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy
Abstract Background This study examined the usefulness of cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels as a candidate biomarker of neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system a...
Main Authors: | Takayuki Katayama, Jun Sawada, Kae Takahashi, Osamu Yahara, Naoyuki Hasebe |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-021-00907-3 |
Similar Items
-
Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies
by: P.G. Foulds, et al.
Published: (2012-01-01) -
Association between cerebrospinal fluid pressure and cognition in patients with Alzheimer’s disease and Lewy body dementia
by: Xia Yang, et al.
Published: (2024-01-01) -
The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
by: Carla Abdelnour, et al.
Published: (2020-01-01) -
Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies
by: Aikaterini Foska, et al.
Published: (2022-04-01) -
Cerebrospinal Fluid Biomarkers in Parkinson’s Disease: A Critical Overview of the Literature and Meta-Analyses
by: Takayuki Katayama, et al.
Published: (2020-07-01)